Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial

scientific article published on 03 May 2018

Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1055/S-0038-1645856
P698PubMed publication ID29723874

P50authorJeffrey I. WeitzQ29561411
Robert P GiuglianoQ59559995
Elliott M AntmanQ64496972
James DouketisQ100404477
Sabina A MurphyQ114308442
P2093author name stringEugene Braunwald
Christian T Ruff
Michele F Mercuri
Laura T Grip
P433issue6
P921main subject(RS)-warfarinQ407431
atrial fibrillationQ815819
P304page(s)1001-1008
P577publication date2018-05-03
P1433published inThrombosis and HaemostasisQ15724413
P1476titlePeri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial
P478volume118

Reverse relations

cites work (P2860)
Q56516532Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE) - Trial Design
Q93377019Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide
Q92983756Perioperative interruption of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: A comparative analysis
Q99618868Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study
Q94677081Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study

Search more.